Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
Provided By GlobeNewswire
Last update: May 5, 2025
MaGic trial exceeded enrollment target of 60 patients
Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26
Read more at globenewswire.com
